Your browser is no longer supported. Please, upgrade your browser.
MESO [NASD]
Mesoblast Limited
Index- P/E- EPS (ttm)-0.89 Insider Own- Shs Outstand116.50M Perf Week12.24%
Market Cap1.14B Forward P/E88.36 EPS next Y0.11 Insider Trans- Shs Float115.83M Perf Month-42.69%
Income-97.00M PEG- EPS next Q-0.25 Inst Own2.90% Short Float2.90% Perf Quarter-19.27%
Sales16.40M P/S69.81 EPS this Y18.90% Inst Trans-0.50% Short Ratio4.13 Perf Half Y-17.35%
Book/sh4.62 P/B2.10 EPS next Y133.30% ROA-13.80% Target Price14.96 Perf Year25.42%
Cash/sh0.92 P/C10.60 EPS next 5Y48.80% ROE-18.70% 52W Range3.12 - 21.28 Perf YTD14.49%
Dividend- P/FCF- EPS past 5Y13.10% ROI-9.80% 52W High-54.32% Beta3.74
Dividend %- Quick Ratio1.30 Sales past 5Y10.20% Gross Margin- 52W Low211.53% ATR1.05
Employees102 Current Ratio1.30 Sales Q/Q-92.40% Oper. Margin- RSI (14)43.59 Volatility8.91% 6.93%
OptionableYes Debt/Eq0.19 EPS Q/Q-283.80% Profit Margin- Rel Volume1.12 Prev Close9.83
ShortableNo LT Debt/Eq0.12 Earnings- Payout- Avg Volume814.70K Price9.72
Recom2.40 SMA200.23% SMA50-19.66% SMA200-22.25% Volume906,327 Change-1.12%
Dec-22-20Downgrade Maxim Group Buy → Hold
Dec-04-20Downgrade Chardan Capital Markets Neutral → Sell $7.50
Oct-22-20Initiated RBC Capital Mkts Sector Perform $12
Aug-14-20Reiterated Maxim Group Buy $16 → $22
May-28-20Reiterated H.C. Wainwright Buy $14 → $21
Jan-31-19Resumed H.C. Wainwright Buy $6.50
Mar-22-18Downgrade Credit Suisse Neutral → Underperform
Feb-28-18Reiterated Cantor Fitzgerald Buy $20 → $23
Aug-31-17Initiated Oppenheimer Outperform $16
Jun-08-17Initiated Cantor Fitzgerald Buy
Jan-12-21 09:32AM  
08:48AM  
Jan-11-21 05:10PM  
04:43PM  
Jan-10-21 11:26PM  
Dec-21-20 09:47AM  
Dec-18-20 04:46PM  
Dec-17-20 10:07PM  
06:32PM  
Dec-15-20 12:56PM  
Dec-14-20 05:27PM  
04:56PM  
Dec-08-20 09:12AM  
08:15AM  
Dec-07-20 04:33PM  
03:00PM  
01:30PM  
12:45PM  
10:12AM  
10:05AM  
10:00AM  
08:42AM  
06:20AM  
06:00AM  
12:20AM  
Dec-06-20 12:30PM  
Dec-05-20 06:32PM  
10:45AM  
Dec-04-20 09:00PM  
12:15PM  
11:00AM  
09:39AM  
09:30AM  
08:00AM  
Dec-03-20 07:10PM  
06:45PM  
02:15PM  
01:00PM  
11:00AM  
09:33AM  
Dec-02-20 11:24AM  
11:00AM  
09:38AM  
06:00AM  
Dec-01-20 09:40PM  
09:00PM  
06:30PM  
05:55PM  
11:30AM  
11:15AM  
11:00AM  
10:10AM  
09:20AM  
Nov-30-20 01:52PM  
01:00PM  
12:30PM  
12:00PM  
06:30AM  
Nov-29-20 01:00PM  
Nov-28-20 11:00PM  
02:00PM  
Nov-27-20 01:07PM  
01:00PM  
Nov-26-20 09:03AM  
06:20AM  
Nov-25-20 10:23PM  
11:35AM  
11:00AM  
Nov-24-20 08:28PM  
07:00PM  
04:25PM  
04:00PM  
01:35PM  
01:00PM  
12:00PM  
11:30AM  
06:20AM  
Nov-23-20 11:00PM  
01:27PM  
01:10PM  
12:00PM  
11:45AM  
11:00AM  
06:25AM  
Nov-22-20 12:32AM  
Nov-21-20 01:06PM  
Nov-20-20 07:06PM  
11:20AM  
10:17AM  
Nov-19-20 05:40PM  
05:36PM  
05:21PM  
05:12PM  
04:19PM  
06:20AM  
Nov-18-20 10:00PM  
09:44PM  
09:15PM  
07:43PM  
05:45PM  
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grunenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.